Clinical study of Yangyin Jiedu Decoction delaying invasion and metastasis of non-small cell lung cancer after operation

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300071693

Enrollment

Unknown

Registered

2023-05-22

Start date

2023-05-12

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer (NSCLC)

Interventions

control group:Placebo for Yangyin Jiedu Decoction

treatment group:Yangyin Jiedu Decoction

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1)The patient underwent radical lung cancer surgery and was diagnosed with NSCLC by pathology or cytology; (2)The patients were diagnosed as stage II-III according to the 8th edition of UICC 2017 TNM staging criteria; (3)The patient has completed or does not require radiotherapy, chemotherapy, targeted therapy, or immunotherapy during the trial period; (4)The dialectical classification of traditional Chinese medicine conforms to the deficiency of both qi and yin; (5)The age ranges from 18 to 85 years old; (6)The Karnofsky Performance status (KPS) score was more than 70; (7)The patient's expected survival period is more than 3 months; (8)The patient and their family members understand the situation of this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1)The patient had other tumors within 5 years prior to enrollment; (2)Patients with severe heart, brain, liver, kidney disease, and hematological system disease; (3)The patient has severe infection; (4)Pregnant or lactating patients; (5)Patients with mental disorders who cannot cooperate with treatment; (6) Patients with poor compliance; (7) Individuals who are allergic to any traditional Chinese medicine in the research formula; (8) Patients who have participated in other trials or treatments in the past 3 months.

Design outcomes

Primary

Measure	Time frame
Disease-Free Survival(DFS);Overall Survival(OS);Safety index;	—

Secondary

Measure	Time frame
The quality of life;TCM clinical syndromes and symptoms;Serum tumor markers;Lymphocyte subtype;	—

Countries

China

Contacts

Public ContactWang Zhongqi

Longhua Hospital, Shanghai University of Traditional Chinese Medicine

aledx@sina.com+86 136 3662 3819

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026